Stock Events

Stock Events

Black Diamond Therapeutics 

$2.12
106
+$0.02+0.95% Friday 20:00
+$0.02+0.94%Friday 23:20After hours

Statistics

Day High
2.12
Day Low
2.11
52W High
4.94
52W Low
1.6
Volume
8,968
Avg. Volume
-
Mkt Cap
121.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.31
0.12
0.55
0.98
Expected EPS
-0.09375
Actual EPS
N/A

Financials

31.95%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
70MRevenue
22.37MNet Income

Analyst Ratings

12.50Average Price Target
The highest estimate is 14.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BDTX. It's not an investment recommendation.
NVIDIA
20
NVDA
Amazon
18
AMZN
Microsoft
17
MSFT
Tesla
16
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of cancer treatment research, which puts it in direct competition with Black Diamond's approach to targeting mutations.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including targeted therapies that compete with Black Diamond's precision oncology products.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a strong presence in the cancer treatment market, including targeted therapies and immunooncology, competing with Black Diamond's cancer focus.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse oncology portfolio, including precision medicine and targeted therapies, making it a competitor in the same space as Black Diamond.
Merck
MRK
Mkt Cap366B
Merck is known for its cancer treatments, including targeted therapy and immunotherapy options, competing with Black Diamond's targeted cancer therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has expanded its oncology portfolio, including cell therapies and targeted treatments, positioning it as a competitor to Black Diamond.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of cancer treatments, including targeted therapies that compete with Black Diamond's approach to precision oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals focuses on developing drugs for cancer, among other diseases, with a strategy that includes precision medicine, competing with Black Diamond.

About

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Show more...
CEO
Mark A. Velleca
Employees
21
Country
United States
ISIN
US09203E1055

Listings

XNAS
US
BDTX
BOATS
BOATS
BDTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Black Diamond Therapeutics stock price today?▼
The current price of BDTX is $2.12 USD — it has increased by +0.95% in the past 24 hours. Watch Black Diamond Therapeutics stock price performance more closely on the chart.
What is Black Diamond Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Black Diamond Therapeutics stocks are traded under the ticker BDTX.
Is Black Diamond Therapeutics stock price growing?▼
BDTX stock has fallen by -4.93% compared to the previous week, the month change is a +18.44% rise, over the last year Black Diamond Therapeutics has showed a -27.89% decrease.
What is Black Diamond Therapeutics market cap?▼
Today Black Diamond Therapeutics has the market capitalization of 121.8M
When is the next Black Diamond Therapeutics earnings date?▼
Black Diamond Therapeutics is going to release the next earnings report on November 09, 2026.
What were Black Diamond Therapeutics earnings last quarter?▼
BDTX earnings for the last quarter are -0.17 USD per share, whereas the estimation was -0.2 USD resulting in a +13.02% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Black Diamond Therapeutics revenue for the last year?▼
Black Diamond Therapeutics revenue for the last year amounts to 70M USD.
What is Black Diamond Therapeutics net income for the last year?▼
BDTX net income for the last year is 22.37M USD.
How many employees does Black Diamond Therapeutics have?▼
As of September 05, 2026, the company has 21 employees.
In which sector is Black Diamond Therapeutics located?▼
Black Diamond Therapeutics operates in the Health & Wellness sector.
When did Black Diamond Therapeutics complete a stock split?▼
Black Diamond Therapeutics has not had any recent stock splits.
Where is Black Diamond Therapeutics headquartered?▼
Black Diamond Therapeutics is headquartered in CAMBRIDGE, United States.